- Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
- Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
- Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx to Participate at Investor Conferences in March
- Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
- Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
- Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
- Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
- Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
More ▼
Key statistics
As of last trade Ultragenyx Pharmaceutical Inc (RARE:NSQ) traded at 44.12, -19.75% below its 52-week high of 54.98, set on Jun 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 44.10 |
---|---|
High | 44.16 |
Low | 43.81 |
Bid | 44.05 |
Offer | 44.14 |
Previous close | 44.11 |
Average volume | 834.25k |
---|---|
Shares outstanding | 82.34m |
Free float | 78.95m |
P/E (TTM) | -- |
Market cap | 3.63bn USD |
EPS (TTM) | -8.33 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 14:59 BST.
More ▼